Thus, the USP7 inhibitors can offer the chance to modulate the growth ability of prostate cancer cells: on one side they can, by downregulating the levels of both isoforms, negatively modulate the AR-FL and the ARV7 dependent proliferative and trascriptional abilities; on the other side by downregulating CCDC6, they can affect the homologous directed DNA repair and sensitize the castration resistant cancer cells to the PARP inhibitors treatment. The gene discussed is PARP1; the disease is prostate carcinoma.